Lts Lohmann Therapie-systeme Ag

Purdue Pharma L.p.

Luye Pharma Switzerland Ag

Gabriel Wauer

Thomas Hille

Frank Seibertz

Patrick Mohr

Marco Emgenbroich

Petra Botzem

Gerhard Ritzdorf

Marlene Fuhrmann

Kevin John Smith

Heiko Spilgies

Andreas Henning

Björn Schurad

Rolf Pracht

Peter Klaffenbach

Nico Reum

Helen Elizabeth Johnson

Helena Gallinger

Hans-Werner Wolf

Shu-Lun Weinheimer

Gillian Elizabeth Mundin

Ulrike Kolling

Christian Benda

The invention relates to a microneedle array, in particular to an applicator system, and to the use thereof for the intradermal delivery of active ingredients in the form of salts, in particular medicinal drugs in the form of salts, wherein this microneedle array is suitable for penetrating the skin of humans or animals, and the microneedles are made of a formulation, containing at least one active ingredient in the form of a salt and at least one biodegradable polymer.

Microneedle array having an active ingredient in the form of salts

The present invention relates to a transdermal therapeutic system (TTS) comprising an active agent-containing layer structure comprising A) a backing layer and B) a biphasic matrix layer, the biphasic matrix layer having a) a continuous, outer phase having a composition comprising 70 to 100% by weight of at least one polymer, b) a discontinuous, inner phase having a composition comprising the active agent and a dissolver for the active agent in amount sufficient so that the active agent forms a solution with the dissolver in the inner phase and c) an emulsifier in an amount of 0.1 to 20% by weight based on the biphasic matrix layer, processes of manufacture and uses thereof, corresponding methods of treatments therewith.

Transdermal delivery system including an emulsifier

Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

Oral dosage form containing theobromine-free cocoa

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.

Transdermal therapeutic system for the transdermal administration of solifenacin

The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

Nicotine-containing transparent transdermal therapeutic system

The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment () and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer () and an adhesive polymer layer () that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layersand

Over-patch having improved compatibility and a long adhesion duration and method for producing said over-patch

A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

Buprenorphine transdermal delivery system

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising

Transdermal delivery system comprising buprenorphine

Growing community of inventors

Ahrweiler, Germany

Gabriel Wauer